Recruiting
Phase 1
Phase 2

KRIYA-825

Sponsor:

Kriya Therapeutics, Inc.

Code:

NCT06765980

Conditions

Geographic Atrophy Secondary to Age-related Macular Degeneration

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Not accepted

Interventions

VV-14295

Study Details

Brief summary:

The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).

Conditions

Geographic Atrophy Secondary to Age-related Macular Degeneration

Study ID

NCT06765980

Start date

May 28, 2025

Status verified date

Sep, 2025

Completion date

Dec 15, 2027

Anticipated

Primary completion date

Dec 15, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participant must be between 55 to 80 years of age (inclusive), at the time of signing the informed consent form.
  • Body mass index (BMI) of 19 to 34 kg/m2 (inclusive).
  • Must agree to use reliable contraception for at least 12 months after administration of VV-14295. A female participant is eligible to participate if she is not pregnant and not breastfeeding.
  • The GA lesion must meet certain criteria as assessed by a central reading center's assessment of imaging at Screening.
  • Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the Investigator.
  • For study eye, Normal Luminance BCVA of 55 letters or worse using the ETDRS charts (20/80 or worse) for Part 1a participants or 24 letters or better (approximately 20/320 Snellen equivalent) for Part 1b and Part 2 participants.
  • Fellow eye Normal Luminance BCVA of 5 letters or better using ETDRS charts (20/800 or better) for Part 1a participants or 24 letters or better (approximately 20/320 Snellen equivalent or better) for Part 1b and Part 2 participants. Fellow eye must have equivalent or better visual acuity than the study eye.

Exclusion Criteria:

  • Any ocular disease or condition that is not GA secondary to AMD: Macular atrophy secondary to a condition other than AMD; Exudative AMD diagnosis or any history of or active macular neovascularization (in study eye or fellow eye) and/or retinal angiomatous proliferation associated with AMD or any other cause; Presence of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function; Active ocular or periocular infection or active uncontrolled intraocular inflammation within 3 months of Screening; History of vitrectomy, retinal detachment, or corneal transplant in the study eye; Active/history of uveitis.
  • Any ocular condition that prevents adequate imaging.
  • Medical, cognitive or psychiatric conditions that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.
  • Hospitalization within 1 year prior to Screening that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.
  • Any Screening test (e.g., ECG) or laboratory value (e.g., hematology) that in the opinion of the Investigator and/or Medical Monitor is clinically significant and renders the participant not suitable for study participation.
  • Participant has a direct contraindication to the steroid regimen (both oral and topical) or has a condition that significantly increases the risk of complication.
  • Active/history of malignancy within the past 5 years from Screening or any previous therapeutic radiation in the region of the study eye(s) at Screening. History of non-melanoma skin cancers (e.g., basal cell, squamous cell carcinomas), cervical intraepithelial neoplasia (CIN), and localized prostate cancer after treatment are not exclusionary.
  • Intraocular surgery (including lens replacement surgery) within 3 months prior to Screening.
  • History of laser therapy in the macular region.
  • History of intravitreal (IVT) therapy, such as IVT steroid injections, within 6 months prior to Screening.
  • COVID-19 vaccine within 90 days of Screening or plan to receive COVID-19 vaccine within 6 months of treatment.
  • Active use of systemic immunomodulatory drugs or systemic corticosteroids in the last 60 days. Topical steroids are not exclusionary.
  • Prior participation in another interventional clinical study for GA within the past 12 months from the last dosing at Screening.

Study Design

Enrollment

62 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Part 1a, low dose

A single low dose of VV-14295 will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

experimental: Part 1a, high dose

A single high dose of VV-14295 will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

experimental: Part 1b

A single dose of VV-14295 determined from Part 1a will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

experimental: Part 2

A single dose of VV-14295 determined from Part 1a will be administered on Day 1. In addition, oral prednisone and difluprednate eye drops will be administered prior to and after VV-14295 dosing to reduce the risk of inflammation. After several weeks, participants will switch from difluprednate to prednisolone acetate eye drops.

Interventions

VV-14295

VV-14295 will be administered as a single suprachoroidal injection.

Primary outcome measure

  • Incidence and severity of ocular and non-ocular adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal electrocardiograms (ECGs), and abnormal ophthalmic findings [ Time Frame: 12 months ]
  • Incidence and severity of ocular and non-ocular adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal ECGs, and abnormal ophthalmic findings [ Time Frame: 12 months ]
  • Rate of GA progression as assessed by optical coherence tomography (OCT) [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

VP, Medical Affairs

984-884-5058clinicaltrials@kriyatx.com

Locations

Kriya Clinical Study Site

Recruiting

Erie, Pennsylvania, United States, 16505

Contacts

VP, Medical Affairs

984-884-5058clinicaltrials@kriyatx.com

Kriya Clinical Study Site

Recruiting

Ottawa, Ontario, Canada

Contacts

VP, Medical Affairs

984-884-5058clinicaltrials@kriyatx.com

More Information

Sponsor

Kriya Therapeutics, Inc.

Last update posted

Aug 10, 2026

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Kriya Therapeutics, Inc. on 2026-08-10.